Core evidence.

clinical impact summary for linezolid in the treatment of methicillin-resistant Staphylococcus aureus (MRSA)

Outcome measure	Evidence	Implications
Disease-oriented evidence	Demonstrates good efficacy for the treatment of infections caused by MRSA	May be used as monotherapy in treating MRSA infections except for bacteremia and/or endocarditis
Patient-oriented evidence	Multiple randomized clinical trials show good outcome data	Careful monitoring for potential adverse events (eg, bone marrow suppression, serotonin syndrome) is necessary while on therapy
Economic evidence	Costly compared to other drugs; should not be used as first line therapy for mild disease in outpatients	Cost-effective for hospitalized patients with serious infections primarily by decreasing length of stay